{"product_id":"thtx-vrio-analysis","title":"Theratechnologies Inc. (THTX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Theratechnologies Inc. (THTX) truly built to last? This VRIO analysis cuts straight to the core, dissecting the Value, Rarity, Inimitability, and Organization of its key resources to reveal the true source of its competitive advantage - or lack thereof. Discover immediately whether Theratechnologies Inc. (THTX)'s current strengths are fleeting or form an unshakeable foundation for market dominance by diving into the detailed findings below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTheratechnologies Inc. (THTX) - VRIO Analysis: Proprietary HIV Drug Portfolio (EGRIFTA Franchise \u0026amp; Trogarzo)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou are looking at the core revenue drivers for Theratechnologies Inc. (THTX), and the numbers from the second quarter of fiscal 2025 tell a clear story about their specialized market position. The combined portfolio is the engine, but the new EGRIFTA WR launch is the critical near-term catalyst you need to track.\u003c\/p\u003e\n\n\u003ch3 id=\"value\"\u003eValue: Near-Term Revenue Base and New Growth Vector\u003c\/h3\u003e\n\u003cp\u003eThe value here is tangible, rooted in current sales and a strategic product evolution. EGRIFTA SV provided a solid foundation in Q2 2025, bringing in $11,131,000 in net sales, even while transitioning to the new product. Concurrently, Trogarzo contributed $6,598,000 in net sales for the same quarter, rounding out the portfolio’s immediate financial impact. The total Q2 2025 revenue hit $17.7 million. The real excitement, however, is the September 5, 2025, launch of EGRIFTA WR™, which simplifies dosing (weekly reconstitution vs. daily) and offers a new, improved product to maintain and grow market share.\u003c\/p\u003e\n\n\u003ch3 id=\"rarity\"\u003eRarity: Differentiated Mechanisms in Niche Indications\u003c\/h3\u003e\n\u003cp\u003eThese aren't me-too drugs; they address specific, hard-to-treat patient populations with unique biological actions. For EGRIFTA (tesamorelin), it remains the \u003cstrong\u003eonly\u003c\/strong\u003e FDA-approved treatment in the U.S. specifically for reducing excess abdominal fat in HIV patients with lipodystrophy. Trogarzo (ibalizumab) is a CD4-directed post-attachment HIV-1 inhibitor, a mechanism that was the first new approach in over a decade for multidrug-resistant (MDR) HIV. This differentiation means they aren't competing head-to-head with the bulk of the HIV market.\u003c\/p\u003e\n\n\u003ch3 id=\"imitability\"\u003eImitability: Legal Barriers Create High Hurdles\u003c\/h3\u003e\n\u003cp\u003eImitation is tough here, not just because of the science, but because of the legal moat. The new EGRIFTA WR formulation is patent protected in the U.S. until 2033. Furthermore, Theratechnologies holds a U.S. patent for tesamorelin related to NASH treatment that is scheduled to expire in 2040. Since Trogarzo is a biologic monoclonal antibody, creating a biosimilar is a multi-year, high-capital endeavor, creating a significant barrier to entry for competitors looking to replicate that specific mechanism of action.\u003c\/p\u003e\n\n\u003ch3 id=\"organization\"\u003eOrganization: Operational Recovery and Focus\u003c\/h3\u003e\n\u003cp\u003eThe company has demonstrated it can organize around its assets effectively, especially after recent operational hiccups. The fact that Theratechnologies reported \u003cstrong\u003erecord high new patient enrollments\u003c\/strong\u003e for EGRIFTA SV following the resolution of the Q1 2025 supply disruption shows strong commercial execution and physician\/patient trust. Management’s focus on the smooth transition to EGRIFTA WR also shows organizational alignment on maximizing the value of the next-generation product.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on how these components stack up:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n    \u003ctr\u003e\n        \u003cth\u003eVRIO Dimension\u003c\/th\u003e\n        \u003cth\u003eResource\/Capability\u003c\/th\u003e\n        \u003cth\u003eScore (Y\/N)\u003c\/th\u003e\n        \u003cth\u003eCompetitive Implication\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eValue (V)\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eEGRIFTA SV Sales \u0026amp; EGRIFTA WR Launch\u003c\/td\u003e\n        \u003ctd\u003eYes\u003c\/td\u003e\n        \u003ctd\u003eMeets customer demand; generates revenue\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eOnly FDA-approved treatment for HIV lipodystrophy fat reduction (EGRIFTA)\u003c\/td\u003e\n        \u003ctd\u003eYes\u003c\/td\u003e\n        \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eRarity (R)\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eNovel CD4 post-attachment inhibition mechanism (Trogarzo)\u003c\/td\u003e\n        \u003ctd\u003eYes\u003c\/td\u003e\n        \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eInimitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eEGRIFTA WR Patent until \u003cstrong\u003e2033\u003c\/strong\u003e\n\u003c\/td\u003e\n        \u003ctd\u003eYes\u003c\/td\u003e\n        \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eInimitability (I)\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eTrogarzo Biologic Complexity\u003c\/td\u003e\n        \u003ctd\u003eYes\u003c\/td\u003e\n        \u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003e\u003cstrong\u003eOrganization (O)\u003c\/strong\u003e\u003c\/td\u003e\n        \u003ctd\u003eStrong patient enrollment recovery post-supply issue\u003c\/td\u003e\n        \u003ctd\u003eYes\u003c\/td\u003e\n        \u003ctd\u003eRealizing Temporary Advantage\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the risk of reimbursement coverage for EGRIFTA WR, which management noted as a key uncertainty. Still, the patent protection on the core molecules gives them a strong runway.\u003c\/p\u003e\n\u003cul\u003e\n    \u003cli\u003eEGRIFTA SV Q2 2025 Net Sales: \u003cstrong\u003e$11,131,000\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eTrogarzo Q2 2025 Net Sales: \u003cstrong\u003e$6,598,000\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eEGRIFTA WR U.S. Patent Expiration: \u003cstrong\u003e2033\u003c\/strong\u003e\n\u003c\/li\u003e\n    \u003cli\u003eTesamorelin NASH Patent Expiration: \u003cstrong\u003e2040\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe current state points toward a \u003cstrong\u003eTemporary Competitive Advantage\u003c\/strong\u003e, which, with the new WR launch and strong organization, is being actively managed toward a sustained advantage.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTheratechnologies Inc. (THTX) - VRIO Analysis: US Commercialization and Market Access Infrastructure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for direct-to-market access and reimbursement negotiation for specialized therapies in the lucrative US market.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many biotechs lack established, focused commercial teams for niche areas like this.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; building a specialized sales force and securing payer contracts takes years and significant capital.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective, as the company was able to quickly pivot and prepare for the EGRIFTA WR™ launch, receiving FDA Approval for EGRIFTA WR™ (Tesamorelin F8) on March 25, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the infrastructure is valuable but could be absorbed or replicated by a larger entity like Future Pak, which entered into a definitive agreement to acquire Theratechnologies subsequent to Q2 2025 quarter end.\u003c\/p\u003e\n\u003cp\u003eThe performance of the commercial infrastructure is evidenced by product sales figures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEGRIFTA SV® net sales for the three months ended August 31, 2024, were \u003cstrong\u003e$16,687,000\u003c\/strong\u003e, representing a \u003cstrong\u003e26.6%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eEGRIFTA SV® net sales for the six-month period ended May 31, 2024, were \u003cstrong\u003e$25,786,000\u003c\/strong\u003e, showing \u003cstrong\u003e9.4%\u003c\/strong\u003e growth.\u003c\/li\u003e\n\u003cli\u003eThe company increased its Fiscal 2024 Adjusted EBITDA guidance to a range of \u003cstrong\u003e$17 million to $19 million\u003c\/strong\u003e, up from the initial guidance of \u003cstrong\u003e$13 million to $15 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company maintained a strong cash position of close to \u003cstrong\u003e$39 million\u003c\/strong\u003e at the end of Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (USD)\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003cth\u003eQ3 2023\u003c\/th\u003e\n\u003cth\u003eYoY Change\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEGRIFTA SV® Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16,687,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$13,183,000\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+26.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrogarzo® Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,913,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$7,672,000\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-22.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsolidated Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$22,600,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$20,855,000\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+8.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eTheratechnologies Inc. (THTX) - VRIO Analysis: Intellectual Property (IP) for Tesamorelin and Ibalizumab\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis focuses on the exclusive rights derived from Intellectual Property for the commercialized products EGRIFTA SV\/WR (Tesamorelin) and Trogarzo (Ibalizumab).\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eThe IP secures the exclusive right to market EGRIFTA SV\/WR and Trogarzo, underpinning all revenue streams.\u003c\/p\u003e\n\u003cp\u003eThe value is demonstrated by recent net sales figures:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ2 Fiscal 2024 (ended May 31, 2024)\u003c\/td\u003e\n\u003ctd\u003eQ2 Fiscal 2023 (ended May 31, 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEGRIFTA SV® Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16,200,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,853,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrogarzo® Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,817,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6,696,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFor the six-month period ended May 31, 2024, EGRIFTA SV® net sales were \u003cstrong\u003e$25,786,000\u003c\/strong\u003e, and Trogarzo® net sales were \u003cstrong\u003e$12,478,000\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eCore patents and regulatory exclusivities are unique to the company, establishing rarity.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTesamorelin (EGRIFTA) US patents for use in HIV-associated lipodystrophy were scheduled to expire in \u003cstrong\u003eAugust 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIbalizumab (Trogarzo) has an extended period of US exclusivity through to \u003cstrong\u003e2025\u003c\/strong\u003e due to orphan drug status.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eIP is legally protected and difficult to circumvent, providing sustained inimitability.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe US patent for the Tesamorelin F8 Formulation could protect against biosimilar versions until \u003cstrong\u003e2033\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eA patent use claim for Ibalizumab (WO21062546) has a listed expiration date of \u003cstrong\u003eOctober 1, 2040\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe US composition of matter patent for Ibalizumab (US-05871732) expired in \u003cstrong\u003e2016\u003c\/strong\u003e, subject to extensions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe company is well-managed, successfully defending and leveraging its rights through the acquisition and operational performance.\u003c\/p\u003e\n\u003cp\u003eThe company achieved a record positive Adjusted EBITDA of \u003cstrong\u003e$20 million\u003c\/strong\u003e for Fiscal 2024.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage is sustained as long as key patents remain in force, with the longest noted exclusivity extending to \u003cstrong\u003e2040\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTheratechnologies Inc. (THTX) - VRIO Analysis: Regulatory Navigation Expertise (FDA)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eRegulatory Navigation Expertise (FDA)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Critical for maintaining product supply and launching new formulations, as shown by the successful filing and approval of the Prior Approval Supplement (PAS) for EGRIFTA SV in \u003cstrong\u003eApril 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestone\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003ctd\u003eFinancial\/Statistical Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePAS Filing for EGRIFTA SV\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecember 18, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupply shortage estimated to impact 2025 revenue by \u003cstrong\u003e$10 to $12 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Approval of PAS for EGRIFTA SV\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eApril 7, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRemoved discretionary product release requirement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEGRIFTA SV Q2 2025 Sales\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003eDeclined \u003cstrong\u003e31.3%\u003c\/strong\u003e to \u003cstrong\u003e$11.1 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many firms have regulatory teams, but success in complex post-approval supplements is not guaranteed.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe PAS review by the FDA typically takes within four months of receipt.\u003c\/li\u003e\n\u003cli\u003eThe Company filed the PAS on \u003cstrong\u003eDecember 18, 2024\u003c\/strong\u003e, and received approval on \u003cstrong\u003eApril 7, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; processes can be learned, but institutional knowledge of specific FDA interactions is harder to copy.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe supply disruption was caused by an unexpected voluntary shutdown of the contract manufacturer's facility in the third quarter of 2024 following an FDA inspection.\u003c\/li\u003e\n\u003cli\u003eManufacturing resumed in \u003cstrong\u003eNovember 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Highly organized in this area, successfully resolving a major supply chain issue with regulatory clearance.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAchieved positive Adjusted EBITDA of \u003cstrong\u003e$906,000\u003c\/strong\u003e in Q2 2025, marking the fifth consecutive quarter.\u003c\/li\u003e\n\u003cli\u003eReported positive operating cash flow of \u003cstrong\u003e$2.7 million\u003c\/strong\u003e for the first half of 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; a necessary operational capability rather than a long-term differentiator post-acquisition.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe supply uncertainty resulted in a net loss of \u003cstrong\u003e$4.5 million\u003c\/strong\u003e for Q2 2025, compared to a net profit of \u003cstrong\u003e$987,000\u003c\/strong\u003e in Q2 2024.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Total Revenue was \u003cstrong\u003e$19 million\u003c\/strong\u003e, representing a \u003cstrong\u003e17%\u003c\/strong\u003e growth year-over-year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTheratechnologies Inc. (THTX) - VRIO Analysis: Contract Manufacturing Management and Supply Chain Recovery\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: The ability to quickly recover from the late 2024\/early 2025 supply disruption, which cost an estimated $10 to $12 million in lost sales, and resume regular distribution.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe financial impact of the supply disruption on EGRIFTA SV® net sales in the second quarter of 2025 was a decline of \u003cstrong\u003e31.3%\u003c\/strong\u003e year-over-year, equating to sales of \u003cstrong\u003e$11,131,000\u003c\/strong\u003e compared to \u003cstrong\u003e$16,200,000\u003c\/strong\u003e in the second quarter of fiscal 2024. The initial risk assessment estimated a shortfall of approximately \u003cstrong\u003eUS$1.6 million\u003c\/strong\u003e in revenue for fiscal year 2024.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Date\u003c\/th\u003e\n\u003cth\u003eReference Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEGRIFTA SV® Q2 2025 Net Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11,131,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2024 Net Sales: $16,200,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEGRIFTA SV® Q2 Sales Decline\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDue to supply disruption and chargebacks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturer Resumed Manufacturing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNovember 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFollowing voluntary shutdown\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrior Approval Supplement (PAS) Filed\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eDecember 18, 2024\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRequired to resume distribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA PDUFA Goal Date for PAS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eApril 18, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReview timeline for resumed distribution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Adjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$906,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFifth consecutive quarter of positive Adjusted EBITDA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; many companies rely on CMOs (Contract Manufacturing Organizations), but rapid recovery from an FDA-related shutdown is a specific skill.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe disruption stemmed from an unexpected voluntary shutdown of the contract manufacturer's facility following an inspection by the US Food and Drug Administration (FDA).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Temporary; the specific relationship and recovery protocols are not easily transferable.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe recovery involved specific regulatory steps and coordination with the CMO:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe manufacturer addressed observations from the FDA Office of Compliance.\u003c\/li\u003e\n\u003cli\u003eThe manufacturer planned to resume activities by \u003cstrong\u003emid-October\u003c\/strong\u003e (planned timeline).\u003c\/li\u003e\n\u003cli\u003eThe Company filed the required Prior Approval Supplement (PAS) with the FDA on \u003cstrong\u003eDecember 18, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Proven effective under duress, showing operational agility.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOperational agility was demonstrated by achieving positive Adjusted EBITDA of \u003cstrong\u003e$906,000\u003c\/strong\u003e in Q2 2025, despite the revenue impact from the supply shortage in the first quarter of Fiscal 2025. The company also reported a positive \u003cstrong\u003eAdjusted EBITDA of $2.3 million\u003c\/strong\u003e for the first quarter of 2025, mainly related to reloading the pipeline post-disruption.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary; the immediate crisis is over, and Future Pak's infrastructure will likely supersede this specific capability.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company entered into a definitive agreement to be acquired by an affiliate of Future Pak. The acquisition was expected to complete around \u003cstrong\u003eSeptember 25, 2025\u003c\/strong\u003e. The total consideration valued THTX at up to \u003cstrong\u003eUS$3.01 per share\u003c\/strong\u003e in cash plus contingent value rights (CVR) of up to \u003cstrong\u003eUS$1.19 per share\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTheratechnologies Inc. (THTX) - VRIO Analysis: Specialized R\u0026amp;D and Pipeline Integration Capability\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialized R\u0026amp;D and Pipeline Integration Capability\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The internal capacity to prepare for the market introduction of in-licensed products, evidenced by increased selling expenses for market preparation in early 2025.\u003c\/p\u003e\n\u003cp\u003eThe company demonstrated this value by securing exclusive Canadian rights to two investigational RNA-targeted medicines from Ionis Pharmaceuticals, committing resources for their commercialization pathway in Canada. The company is responsible for filing and obtaining regulatory approval in Canada for both olezarsen and donidalorsen, with submissions planned for \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Component\u003c\/th\u003e\n\u003cth\u003eAmount (USD)\u003c\/th\u003e\n\u003cth\u003eSource\/Condition\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment to Ionis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUpon execution of the agreement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Milestone Payments to Ionis\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$12.75 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eBased on regulatory milestones, public reimbursement, and annual sales targets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported for the second quarter of 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSix Months 2025 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$36.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor the first six months of Fiscal 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; it shows an ability to integrate external science into a commercial plan.\u003c\/p\u003e\n\u003cp\u003eThis capability is evidenced by the successful execution of the licensing agreement with Ionis, expanding the portfolio beyond the foundational HIV business. The agreement covers olezarsen (for familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia (sHTG)) and donidalorsen (for hereditary angioedema (HAE)).\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSecured exclusive rights in \u003cstrong\u003eCanada\u003c\/strong\u003e for the specified Ionis assets.\u003c\/li\u003e\n\u003cli\u003eThe company's President and CEO noted this partnership expands the range of treatments beyond the foundational HIV portfolio.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; depends on the quality of the specific in-licensing deals (like the Ionis products).\u003c\/p\u003e\n\u003cp\u003eThe imitability is tied to the specific terms and the clinical\/commercial success of the licensed assets. The agreement includes a financial obligation structure that is specific to this integration effort.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIonis is entitled to receive \u003cstrong\u003etiered double-digit royalties\u003c\/strong\u003e on annual net sales of each medicine.\u003c\/li\u003e\n\u003cli\u003eThe FDA decision for donidalorsen was anticipated by \u003cstrong\u003eAugust 21, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Developing; the focus is shifting from internal discovery to commercializing acquired\/licensed assets.\u003c\/p\u003e\n\u003cp\u003eThe organizational structure was adapting to support the commercialization of licensed assets, though this phase was curtailed by the subsequent acquisition.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company achieved positive Adjusted EBITDA for the \u003cstrong\u003efifth consecutive quarter\u003c\/strong\u003e as of Q2 2025, reaching \u003cstrong\u003e$906,000\u003c\/strong\u003e in that quarter.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative expenses increased significantly due to sale process costs subsequent to Q2 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; this capability is now being folded into the acquirer's larger structure.\u003c\/p\u003e\n\u003cp\u003eThe temporary nature of the advantage is realized through the definitive agreement to be acquired by an affiliate of Future Pak, which was completed on \u003cstrong\u003eSeptember 25, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe company reported a net loss of \u003cstrong\u003e$4.5 million\u003c\/strong\u003e for Q2 2025, compared to a net profit of \u003cstrong\u003e$987,000\u003c\/strong\u003e in Q2 2024.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTheratechnologies Inc. (THTX) - VRIO Analysis: Intangible Asset Value from Commercialization Rights\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eIntangible Asset Value from Commercialization Rights\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe recognized value of the rights to market the products, primarily EGRIFTA SV® and Trogarzo®, is reflected in the amortization expense recorded within selling expenses. For the six-month period ended May 31, 2025, the recorded amortization expense was \u003cstrong\u003e$722,000\u003c\/strong\u003e. This compares to \u003cstrong\u003e$720,000\u003c\/strong\u003e for the same six-month period in Fiscal 2024. The three-month period ended May 31, 2025, saw an amortization expense of \u003cstrong\u003e$361,000\u003c\/strong\u003e, slightly higher than the \u003cstrong\u003e$360,000\u003c\/strong\u003e recorded in the corresponding three-month period of Fiscal 2024. The asset's value is directly tied to the revenue-generating potential of these exclusive marketing territories and products.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePeriod Ended\u003c\/th\u003e\n\u003cth\u003eAmortization Expense (USD)\u003c\/th\u003e\n\u003cth\u003eProduct Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMay 31, 2025 (Six Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$722,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEGRIFTA SV® and Trogarzo® rights\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMay 31, 2024 (Six Months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$720,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEGRIFTA SV® and Trogarzo® rights\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal 2024 (Full Year)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,440,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEGRIFTA SV® and Trogarzo® rights\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFiscal 2023 (Full Year)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,513,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEGRIFTA SV® and Trogarzo® rights\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eHigh\u003c\/strong\u003e; these rights are unique contractual assets tied to specific territories and products, often involving significant regulatory hurdles for replication. The commercialization rights for EGRIFTA SV® in the United States are particularly rare as it is the only FDA-approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy as of February 2023. The rights for Trogarzo® in the United States and Canada are licensed from TaiMed Biologics, Inc.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEGRIFTA SV®: Only FDA-approved treatment in the U.S. for HIV-related excess visceral abdominal fat.\u003c\/li\u003e\n\u003cli\u003eTrogarzo®: Was the first HIV treatment approved with a new mechanism of action in over 10 years (as of March 2018 approval).\u003c\/li\u003e\n\u003cli\u003eGeographic Exclusivity: Theratechnologies focused on North American commercialization, returning European rights for Trogarzo® to TaiMed in 2022.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e; the rights themselves are legally exclusive through contracts and regulatory exclusivity periods. Replicating the value requires either acquiring similar exclusive rights or achieving new regulatory approvals for a substitute product, which is a lengthy and capital-intensive process. The prior termination of agreements to regain worldwide rights for EGRIFTA® in 2019 demonstrates the strategic value placed on controlling these exclusive rights.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe accounting reflects the asset's value through amortization, but the future exploitation and ultimate realization of the asset's full potential are now managed under the definitive agreement for acquisition by an affiliate of Future Pak, which was announced subsequent to Q2 2025. The transaction structure itself, which includes Contingent Value Rights (CVRs) tied to the performance of Trogarzo® and Egrifta, indicates that the organization (Future Pak) is structuring the final value capture around these existing rights.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAcquisition by Future Pak affiliate (CB Biotechnology, LLC) announced in July 2025.\u003c\/li\u003e\n\u003cli\u003eTotal Transaction consideration up to \u003cstrong\u003e$254 million\u003c\/strong\u003e, including CVRs up to an additional \u003cstrong\u003eUS$1.19\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eCVRs are contractual rights tied to sales milestones for Trogarzo® and Egrifta.\u003c\/li\u003e\n\u003cli\u003eThe acquisition is expected to close in the fourth quarter ending November 30, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSustained\u003c\/strong\u003e, as the underlying rights are the foundation of the business value, providing a temporary monopoly for specific, differentiated treatments in the North American market. The premium paid in the acquisition by Future Pak (up to a \u003cstrong\u003e216%\u003c\/strong\u003e premium over the April 10, 2025 closing price, assuming maximum CVR payment) underscores the high, sustained value attributed to these intangible assets.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eTheratechnologies Inc. (THTX) - VRIO Analysis: Financial Stability and Cash Flow Generation\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Generated positive cash flows from operating activities of \u003cstrong\u003e$2,659,000\u003c\/strong\u003e for the six months ended May 31, 2025, which alleviated material uncertainty regarding the going concern. As at May 31, 2025, cash amounted to \u003cstrong\u003e$9,459,000\u003c\/strong\u003e and the accumulated deficit was \u003cstrong\u003e$421,196,000\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; achieving positive operating cash flow while managing product shortages and R\u0026amp;D prep is a solid feat. The company noted an estimated negative impact of \u003cstrong\u003e$10-$12 million\u003c\/strong\u003e from the EGRIFTA SV® shortage in the first quarter of Fiscal 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Temporary; this is a result of past operational efficiency, not a repeatable structural advantage. The positive cash flow for the six-month period was significantly influenced by changes in operating assets and liabilities, including a positive impact of \u003cstrong\u003e$14,082,000\u003c\/strong\u003e in Q2 2025, driven by a decrease in accounts receivable of \u003cstrong\u003e$10,989,000\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong in the short term, as they navigated a tough period to deliver positive cash flow. The company expects its existing cash and operations to fund expenses and debt obligations for at least the next \u003cstrong\u003e12 months\u003c\/strong\u003e as of May 31, 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the acquisition resets the balance sheet and liquidity profile. Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak subsequent to the quarter end.\u003c\/p\u003e\n\n\u003cp\u003eKey financial metrics supporting the analysis for the period ended May 31, 2025:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eSix Months Ended May 31, 2025 (USD)\u003c\/th\u003e\n\u003cth\u003eQ2 Ended May 31, 2025 (USD)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flows from Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2,659,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCash used before changes: \u003cstrong\u003e($1,679,000)\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet (Loss) Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($4,345,000)\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e($4,462,000)\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$36.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$906,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (As at May 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9,459,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFurther details on Q2 2025 performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eTrogarzo® net sales stabilized, generating \u003cstrong\u003e$6.6 million\u003c\/strong\u003e in Q2 2025, a \u003cstrong\u003e13.4%\u003c\/strong\u003e increase year-over-year.\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eEGRIFTA SV® sales declined by \u003cstrong\u003e31.3%\u003c\/strong\u003e in Q2 2025 due to supply disruption and lower unit sales (\u003cstrong\u003e-24.9%\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003e\n\u003c\/li\u003e\n\u003cli\u003eThe company maintained positive Adjusted EBITDA for the \u003cstrong\u003efifth straight quarter\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eTheratechnologies Inc. (THTX) - VRIO Analysis: Transaction Execution and Shareholder Alignment\n\u003c\/h2\u003e\n\n\u003ch\u003eTransaction Execution and Shareholder Alignment\u003c\/h\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e: The successful execution of the Plan of Arrangement, culminating in shareholder approval on \u003cstrong\u003eSeptember 12, 2025\u003c\/strong\u003e and closing on \u003cstrong\u003eSeptember 25, 2025\u003c\/strong\u003e for a deal valued up to \u003cstrong\u003e$3.01\u003c\/strong\u003e cash plus one Contingent Value Right (CVR) per share.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e: High; successfully closing a complex M\u0026amp;A transaction is a rare, high-stakes achievement for a company of this size. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e: N\/A; this is a one-time event, not a repeatable capability. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e: Excellent in the final stages, securing court approval and shareholder buy-in. \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Temporary; this capability is now historical, marking the end of Theratechnologies as an independent entity. \u003c\/p\u003e\n\n\u003cp\u003eKey Financial Terms of the Arrangement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eUpfront Cash Consideration per Share: \u003cstrong\u003e$3.01\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMaximum Potential CVR Payment per Share: Up to \u003cstrong\u003e$1.19\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Potential Consideration per Share: Up to \u003cstrong\u003e$4.20\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMaximum Total Transaction Value: Up to \u003cstrong\u003e$254 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eMaximum Aggregate CVR Payout: \u003cstrong\u003e$65 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFair Market Value of CVR (as of September 24, 2025): \u003cstrong\u003e$0.80\u003c\/strong\u003e per CVR\u003c\/li\u003e\n\u003cli\u003ePremium to Nasdaq Closing Price (April 10, 2025) - Cash Portion: \u003cstrong\u003e126%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePremium to Nasdaq Closing Price (April 10, 2025) - Total Potential Value: \u003cstrong\u003e216%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: Pro-Forma Transaction Proceeds Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Component\u003c\/td\u003e\n\u003ctd\u003ePer Share Amount (USD)\u003c\/td\u003e\n\u003ctd\u003eTotal Potential Amount (USD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Cash Consideration\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.01\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCalculated based on shares outstanding at close\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMaximum CVR Consideration\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.19\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$65 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Potential Consideration\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$4.20\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$254 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCVR Fair Market Value (Valuation Date)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.80\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCalculated based on shares outstanding at close\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516264734869,"sku":"thtx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/thtx-vrio-analysis.png?v=1740223593","url":"https:\/\/dcf-model.com\/fr\/products\/thtx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}